Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02716272 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients(MAPS2) | completed | Phase 2 | 125 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 |
| clinicaltrials |
| NCT02303899 | Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma | completed | Phase 2 | 22 | Istituto Clinico HumanitasOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03048474 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma(INITIATE) | completed | Phase 2 | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01503177 | Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 | 15 | Mayo ClinicOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT00535951 | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT02610140 | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | completed | Phase 2 | 248 | BayerINDUSTRY | 14 | Nov 4, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00128102 | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | completed | Phase 3 | 661 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 26, 2020 | clinicaltrials |
| NCT00295503 | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma | completed | Phase 2 | 53 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02519049 | 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) | completed | — | 30 | Istituto Clinico HumanitasOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT01675765 | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | completed | Phase 1 | 60 | Aduro Biotech, Inc.INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03412357 | MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.(MesoTRAP) | completed | N/A | 23 | Papworth Hospital NHS Foundation TrustOTHER_GOV | 1 | Sep 16, 2020 | clinicaltrials |
| NCT00024076 | Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer | completed | Phase 2 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02151448 | αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies | completed | Phase 1 / Phase 2 | 64 | David BartlettOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02948413 | Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials | completed | — | 55 | National Institutes of Health Clinical Center (CC)NIH | 1 | May 26, 2020 | clinicaltrials |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | completed | Phase 2 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT00299962 | Gene Therapy for Pleural Malignancies | completed | Phase 1 | 17 | University of PennsylvaniaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01119664 | Combination Gene Transfer and Chemotherapy | completed | Phase 1 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT00770120 | S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 61 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2020 | clinicaltrials |
| NCT00372840 | Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer | completed | N/A | 340 | Fox Chase Cancer CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT02194231 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)(ATREUS) | completed | Phase 2 | 145 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00859469 | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00188890 | Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers | completed | — | 1,452 | University Health Network, TorontoOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT04056026 | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma | completed | Early Phase 1 | 1 | ProgenaBiomeOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | completed | Phase 3 | 400 | AGC Biologics S.p.A.INDUSTRY | 12 | Sep 17, 2019 | clinicaltrials |
| NCT01722149 | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | completed | Early Phase 1 | 4 | University of ZurichOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03068117 | Malignant Mesothelioma - Can we Improve Quality of Life(RESPECT-Meso) | completed | N/A | 319 | Portsmouth Hospitals NHS TrustOTHER_GOV | 2 | Jun 13, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00334594 | Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 153 | Swiss Cancer InstituteOTHER | 2 | May 15, 2019 | clinicaltrials |
| NCT02958683 | Chest Wall Motion Analysis in Disease(CWM) | completed | — | 400 | Heart of England NHS TrustOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00484276 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma(NGR010) | completed | Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01358084 | Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM(NGR019) | completed | Phase 2 | 137 | AGC Biologics S.p.A.INDUSTRY | 3 | Jan 15, 2019 | clinicaltrials |
| NCT02585362 | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | completed | N/A | 52 | Kantonsspital Winterthur KSWOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | completed | Phase 2 | 82 | NovoCure Ltd.INDUSTRY | 7 | Sep 25, 2018 | clinicaltrials |
| NCT01776385 | The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma | completed | N/A | 9 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00458913 | Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 82 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01126346 | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(HOPE) | completed | N/A | 10 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00365053 | PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2018 | clinicaltrials |
| NCT01160458 | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00243074 | S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02269878 | Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma | completed | — | 68 | Ain Shams UniversityOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01590472 | Do Your Genes Put You at a Higher Risk of Developing Mesothelioma | completed | — | 69 | Wake Forest UniversityOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01355965 | Autologous Redirected RNA Meso-CIR T Cells | completed | Phase 1 | 18 | University of PennsylvaniaOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT02497508 | Nivolumab in Patients With Recurrent Malignant Mesothelioma(NivoMes) | completed | Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 0 | Sep 14, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2021source: clinicaltrials